Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet).
COVID-19
Management
Multidisciplinary team
Neuroendocrine tumors
Pandemic
Peptide receptors radionuclide therapy
SARS-CoV2
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
17
06
2020
accepted:
09
08
2020
pubmed:
18
8
2020
medline:
23
4
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
The organization of the healthcare system has significantly changed after the recent COVID-19 outbreak, with a negative impact on the management of oncological patients. The present survey reports data collected by the Italian Association for Neuroendocrine Tumors on the management of patients with neuroendocrine neoplasia (NEN) during the pandemic dissemination. A survey with 57 questions was sent to NEN-dedicated Italian centers regarding the management of patients in the period March 9, 2020, to May 9, 2020 RESULTS: The main modification in the centers' activity consisted of decreases in newly diagnosed NEN patients (- 76.8%), decreases in performed surgical procedures (- 58%), delays to starting peptide receptor radionuclide therapy (45.5%), postponed/canceled follow-up examinations (26%), and canceled multidisciplinary teams' activity (20.8%). A low proportion of centers (< 10%) reported having to withdraw systemic anti-tumor medical treatment due to concerns about the pandemic situation, whereas PRRT was withdrawn from no patients. Although the COVID-19 outbreak induced the centers to reduce some important activities in the management of NEN patients, the Italian network was able to provide continuity in care without withdrawing anti-tumor treatment for the majority of patients.
Identifiants
pubmed: 32803662
doi: 10.1007/s40618-020-01393-4
pii: 10.1007/s40618-020-01393-4
pmc: PMC7429140
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
989-994Références
Isidori AM, Jannini EA, Lenzi A, Ghigo E (2020) Board of Full Professors in Endocrinology, Directors of the Endocrinology, Metabolic Disorders Residency Program. The Italian Endo-COVID-19. Our response to the emergency. J Endocrinol Invest. https://doi.org/10.1007/s40618-020-01279-5 (published online ahead of print, 2020 May 8)
doi: 10.1007/s40618-020-01279-5
pubmed: 33128158
pmcid: 7182741
Mistretta FA, Luzzago S, Molendini LO et al (2020) A guide for oncologic patient management during Covid-19 pandemic: the initial experience of an Italian oncologic hub with exemplificative focus on uro-oncologic patients. Cancers (Basel) 12(6):E1513. https://doi.org/10.3390/cancers12061513 (Published 2020 Jun 10)
doi: 10.3390/cancers12061513
Maida M, Sferrazza S, Savarino E et al (2020) Impact of the COVID-19 pandemic on gastroenterology divisions in Italy: a national survey. Dig Liver Dis. https://doi.org/10.1016/j.dld.2020.05.017 (published online ahead of print, 2020 May 16)
doi: 10.1016/j.dld.2020.05.017
pubmed: 32586765
pmcid: 7245276
Liang W, Guan W, Chen R et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21(3):335–337
doi: 10.1016/S1470-2045(20)30096-6
Wang H, Zhang L (2020) Risk of COVID-19 for patients with cancer. Lancet Oncol 21(4):e181
doi: 10.1016/S1470-2045(20)30149-2
Pellino G, Spinelli A (2020) How COVID-19 outbreak is impacting colorectal cancer patients in Italy: a long shadow beyond infection. Dis Colon Rectum. https://doi.org/10.1097/DCR.0000000000001685 (published online ahead of print, 2020 Mar 17)
doi: 10.1097/DCR.0000000000001685
pubmed: 33149034
Corsi F, Caruso A, Albasini S et al (2020) Management of breast cancer in an EUSOMA-accredited breast unit in Lombardy, Italy, during the COVID-19 pandemic. Breast J. https://doi.org/10.1111/tbj.13926.10.1111/tbj.13926 (published online ahead of print, 2020 May 30)
doi: 10.1111/tbj.13926.10.1111/tbj.13926
pubmed: 32475022
pmcid: 7300903
Xu Y, Liu H, Hu K, Wang M (2020) Clinical recommendations on lung cancer management during the COVID-19 pandemic. Thorac Cancer. https://doi.org/10.1111/1759-7714.13498 (published online ahead of print, 2020 May 29)
doi: 10.1111/1759-7714.13498
pubmed: 33325119
pmcid: 7862790
Bergsland EK, Halperin DM, Dillon JS et al (2020) North American neuroendocrine tumor society guide for neuroendocrine tumor patient health care providers during COVID-19. Pancreas. https://doi.org/10.1097/MPA.0000000000001561 (published online ahead of print, 2020 May 19)
doi: 10.1097/MPA.0000000000001561
pubmed: 32675783
pmcid: 7253037
Magi L, Mazzuca F, Rinzivillo M et al (2019) Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center. J Clin Med 8(6):910. https://doi.org/10.3390/jcm8060910 (Published 2019 Jun 25)
doi: 10.3390/jcm8060910
pmcid: 6616416
Grimaldi F, Fazio N, Attanasio R et al (2014) Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 37:875–909
doi: 10.1007/s40618-014-0119-0
Basuroy R, Bouvier C, Ramage JK, Sissons M, Kent A, Srirajaskanthan R (2018) Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic neuroendocrine tumours. Neuroendocrinology 107(1):42–49. https://doi.org/10.1159/000488510
doi: 10.1159/000488510
pubmed: 29550809
Cives M, Strosberg JR (2018) Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 68(6):471–487. https://doi.org/10.3322/caac.21493
doi: 10.3322/caac.21493
pubmed: 30295930
Partelli S, Giannone F, Schiavo Lena M et al (2019) Is the real prevalence of pancreatic neuroendocrine tumors underestimated? a retrospective study on a large series of pancreatic specimens. Neuroendocrinology 109(2):165–170. https://doi.org/10.1159/000499606
doi: 10.1159/000499606
pubmed: 31117106
London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C (2020) Effects of the COVID-19 pandemic on cancer-related patient encounters. JCO Clin Cancer Inform 4:657–665. https://doi.org/10.1200/CCI.20.00068
doi: 10.1200/CCI.20.00068
pubmed: 32716647
Lambertini M, Toss A, Passaro A et al (2020) Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. ESMO Open 5(2):e000759. https://doi.org/10.1136/esmoopen-2020-000759
doi: 10.1136/esmoopen-2020-000759
pubmed: 32229501
Annunziata S, Bauckneht M, Albano D et al (2020) Impact of the COVID-19 pandemic in nuclear medicine departments: preliminary report of the first international survey. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-020-04874-z (published online ahead of print, 2020 May 27)
doi: 10.1007/s00259-020-04874-z
pubmed: 32572561
pmcid: 7308109
Tuech JJ, Gangloff A, Di Fiore F et al (2020) Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic. J Visc Surg. https://doi.org/10.1016/j.jviscsurg.2020.03.008 (published online ahead of print, 2020 Mar 31)
doi: 10.1016/j.jviscsurg.2020.03.008
pubmed: 33272818
pmcid: 7680036
Gill S, Hao D, Hirte H, Campbell A, Colwell B (2020) Impact of COVID-19 on Canadian medical oncologists and cancer care: Canadian Association of Medical Oncologists survey report. Curr Oncol 27(2):71–74. https://doi.org/10.3747/co.27.6643
doi: 10.3747/co.27.6643
pubmed: 32489248
pmcid: 7253737
Chen YM, Perng RP, Chu H, Tsai CM, Whang-Peng J (2004) Impact of severe acute respiratory syndrome on the status of lung cancer chemotherapy patients and a correlation of the signs and symptoms. Lung Cancer 45(1):39–43. https://doi.org/10.1016/j.lungcan.2004.01.002
doi: 10.1016/j.lungcan.2004.01.002
pubmed: 15196733
pmcid: 7133867